The Role of Artificial Intelligence in Antibody Drug Discovery

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines.

By Mandar Bhonde, Appalaraju Jaggupilli, and Rajeshwari B R, all from Enzene.

Antibody-based therapeutics have revolutionized modern medicine through their remarkable specificity and efficacy in targeting cancer, autoimmune, and infectious diseases. More than 100 monoclonal antibodies (mAbs) have gained global clinical approval, reflecting their immense therapeutic demand (1,2). However, conventional discovery workflows, such as hybridoma generation, phage display, and animal immunization, remain slow, resource-intensive, and have high attrition (3,4). These limitations have catalyzed the adoption of artificial intelligence (AI) to reshape the antibody discovery paradigm (5,6).

From Experimental to Computational Discovery

Early experimental platforms, such as hybridoma and phage display, established the foundation for antibody generation but faced inherent constraints in throughput and humanization (3,4). The integration of computational biology introduced in silico tools, including RosettaAntibody, SnugDock, and RosettaAntibodyDesign (RAbD), and enabled structure modeling and affinity optimization (7–9). However, the true transformation within the space came with machine learning (ML) and deep learning (DL) architectures capable of learning directly from biological sequences and structures. Landmark advances, such as AlphaFold2 and RoseTTAFold, achieved near-experimental accuracy in protein structure prediction, dramatically reducing reliance on crystallography and enabling accurate modeling of antibody–antigen complexes (10–12).

Fast-Paced Discovery and Design

AI-driven discovery platforms now accelerate candidate generation by integrating sequence prediction, structure modeling, and binding affinity estimation (12,13). Transformer-based sequence models, such as AntiBERTa and AbLang, learn contextual dependencies across millions of antibody sequences, generating human-like variants with optimized complementarity-determining regions (CDRs) (14,15). Generative AI approaches using diffusion models and variational autoencoders enable de novo antibody design, reducing discovery timelines from years to weeks (16–18). Diffusion-based frameworks, such as RFdiffusion, have achieved atomic-level precision in designing highly specific antibodies, validated by cryo-electron microscopy (19).

Structural and Functional Optimization

AI tools support optimization of key developability attributes — stability, viscosity, aggregation risk, and immunogenicity (19,20). Platforms — examples of which include Therapeutic Antibody Profiler (TAP), and SOLart — incorporate multi-parameter models to predict manufacturability and biophysical performance early in discovery (21,22). This proactive assessment reduces late-stage failures and improves production feasibility. Graph-based models enhance paratope–epitope mapping, improving prediction of antibody–antigen interactions with sub-angstrom precision (6–8).

Integration with High-Throughput Screening

Coupling AI with next-generation sequencing (NGS) and automated laboratory platforms further accelerates discovery (1,23). AI identifies high-affinity and diverse sequences from vast antibody repertoires that might otherwise be overlooked (18,23). ML algorithms using feature embedding have predicted enrichment of rare clones and improved binding specificity (24). This synergy between AI prediction and experimental validation creates a continuous feedback loop supporting rational antibody engineering (18).

Challenges and Future Prospects

Despite significant achievements, challenges persist. Public antibody databases lack paired heavy–light chain information and standardized assay metrics, limiting model generalization (6). Future progress depends on multimodal integration linking structural and omics data with physics-informed AI that merges molecular dynamics with neural networks. Emerging closed-loop discovery ecosystems, where AI designs and robotic systems test in real time, are ushering in autonomous biologic design (25).

The global antibody drug market, projected to surpass USD 445 billion within five years, will benefit enormously from these AI innovations. As Agentic AI systems combine literature mining and iterative optimization, discovery becomes faster and more democratized (Figure 1)(26). AI promises to expand antibody design beyond natural limitations, enabling development of bispecifics and antibody–drug conjugates for previously undruggable targets, heralding a new age of AI-orchestrated therapeutic discovery (6)

Source : www.thepharmanavigator.com